RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM ...
RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of ...
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate ...
Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate: the small molecule RTY-694, which is meant to treat the rare liver disease ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter ...
One of the quirks about drug hunting is that finding new medicines doesn’t always mean uncovering something completely new. Sometimes it’s about revisiting previously hunted grounds and spotting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results